^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | petosemtamab (MCLA-158) (EGFR antagonist, LGR5 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors
Published date:
04/25/2022
Excerpt:
MCLA-158 exhibits therapeutic properties such as growth inhibition of KRAS-mutant colorectal cancers...
DOI:
10.1038/s43018-022-00359-0
